Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome

British Journal of Rheumatology

Volumn 36, Issue 9, 1997, Pages 964-968

  Amengual, O ^a   Atsumi, T ^a   Khamashta, M A ^a   Tinahones, F ^b   Hughes, G R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Anti 2 glycoprotein I antibodies; Anticardiolipin antibodies; Atherosclerosis; Systemic lupus erythematosus; Thrombosis

Indexed keywords

ANTIBODY; ANTIGEN; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030867292     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.9.964     Document Type: Article

References (31)

1. Brown MS, Goldstein JL. The hyperlipoproteinemias and other disorders of lipid metabolism. In: Isselbacher KJ, ed. Harrison's principles of internal medicine, 13th edn, Vol. 2. New York: McGraw-Hill, Inc. 1994:2058-69.
2. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995;102:174-80.
3. Palinski W, Rosenfeld ME, Ylä-Herttuala S et al. Low-density lipoprotein undergoes oxidative modifications in vivo. Proc Natl Acad Sci USA 1989;86:1372-6.
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JD, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
5. Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. J Am Med Assoc 1990;264: 3047-52.
6. Ylä-Herttuala S, Palinski W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;85:1086-95.
7. O'Brien KD, Alpers CE, Hokanson JE, Wang S, Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation 1996;94:1216-25.
8. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88: 1785-92.
9. Berliner JA, Territo MC, Sevanian A et al. Minimally modified low-density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-6.
10. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990;114:383-7.
11. Salonen JK, Ylä-Herttuala S, Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
12. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
13. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341-4.
14. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990;74:1-9.
15. Palinski W, Ylä-Herttuala S, Rosenfeld ME et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-35.
16. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol, 1996;35:1239-43.
17. Khoo JC, Miller E, Pio F, Steinberg D, Witztum JL. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992;12:1258-66.
18. Puurunen M, Mänttäri M, Manninen V et al. Antibody against low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-9.
19. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995;44:60-6.
20. Boullier A, Hamon M, Walters-Laporte E et al. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta 1995;238:1-10.
21. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45: 876-83.
22. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. Hypertension 1995;13:129-38.
23. Vaarala O, Puurunen M, Lukka G et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol 1996;104:269-74.
24. Palinski W, Hörkkö S, Miller E et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. J Clin Invest 1996;98:800-14.
25. Hörkkö S, Miller E, Dudl E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996;98:815-25.
26. Mizutani H, Kurata Y, Kosugi S et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand White x BXSB)F1 mouse model of anti-phospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995;38:1382-8.
27. Matsuura E, Katahira T, Igarashi Y, Koike T. β2-Glycoprotein I bound to oxidatively modified lipoproteins could be targeted by anticardiolipin antibodies. Lupus 1994;3:314.
28. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid' autoantibodies. Blood 1994;84:2854-67.
29. Ames PRJ. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying 'Membrane stress syndrome' hypothesis. Lupus 1994;3:371-7.
30. Asherson RA, Khamashta MA, Baguley E, Oakley CM, Rowell NR, Hughes GRV. Myocardial infarction and antiphospholipid antibodies in systemic lupus erythematosus and related disorders. Q J Med 1989;73:1103-15.
31. Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oaley MJ. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990;82:369-75.